scholarly journals Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center

Cancer ◽  
2011 ◽  
Vol 118 (5) ◽  
pp. 1422-1428 ◽  
Author(s):  
Ignacio Garrido-Laguna ◽  
Filip Janku ◽  
Christos Vaklavas ◽  
Gerald S. Falchook ◽  
Siqing Fu ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Phase I ◽  
Prognostic Score ◽  
Cancer Center ◽  
Phase I Clinical Trials ◽  
Royal Marsden Hospital ◽  
Md Anderson

scholarly journals Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience

Oncotarget ◽  
2017 ◽  
Vol 8 (50) ◽  
pp. 87163-87173
Author(s):  
Jennifer B. Goldstein ◽  
Chad Tang ◽  
Kenneth R. Hess ◽  
David Hong ◽  
Vivek Subbiah ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Clinical Trials ◽  
Phase I ◽  
Advanced Pancreatic Cancer ◽  
Cancer Center ◽  
Phase I Clinical Trials ◽  
Md Anderson

scholarly journals Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience

2011 ◽  
Vol 16 (9) ◽  
pp. 1292-1298 ◽  
Author(s):  
Hazem El‐Osta ◽  
David Hong ◽  
Jennifer Wheler ◽  
Siqing Fu ◽  
Aung Naing ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Phase I ◽  
Cancer Center ◽  
Phase I Clinical Trials ◽  
Md Anderson

scholarly journals Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

2012 ◽  
Vol 18 (22) ◽  
pp. 6373-6383 ◽  
Author(s):  
Apostolia-Maria Tsimberidou ◽  
Nancy G. Iskander ◽  
David S. Hong ◽  
Jennifer J. Wheler ◽  
Gerald S. Falchook ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Personalized Medicine ◽  
Phase I ◽  
Cancer Center ◽  
Phase I Clinical Trials ◽  
Md Anderson

Characteristics and outcomes of patients with gallbladder cancer and cholangiocarcinoma referred to a phase I clinic.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 364-364 ◽  
Author(s):  
Ishwaria Mohan Subbiah ◽  
Vivek Subbiah ◽  
Ahmed Omar Kaseb ◽  
Filip Janku ◽  
Jennifer J. Wheler ◽  
...  
Keyword(s):  
Overall Survival ◽  
Clinical Trials ◽  
Phase I ◽  
Median Time ◽  
Median Survival ◽  
Phase I Trial ◽  
Mutational Analysis ◽  
Phase 1 ◽  
Cancer Center ◽  
Phase I Clinical Trials

364 Background: The prognosis of cholangiocarcinoma (CC) and gallbladder carcinoma (GC) remains grim. The purpose of this study was to report the presenting characteristics and outcomes of patients with CC and GC treated on phase 1 clinical trials focused on targeted agents at a major cancer center. Methods: We reviewed the records of consecutive patients with GC and CC in the Phase I Clinical Trials Program at the M. D. Anderson Cancer Center from Nov 2004. We assessed the relationship between overall survival, patients' tumor types, and mutations, demographic and clinical characteristics. Results: Fifty-two patients were identified (7 with GC, 45 with CC). The median age was 58 yrs (range, 20-75 yrs). ECOG performance status (PS) was 0, 1, 2, and 3 in 9 (17%), 30 (58%), 7 (13%), and 6 (12%) pts, respectively. Median number of prior therapies was 3 (range 0-17). The median time from diagnosis of metastatic disease to primary Phase I clinic evaluation was 14.6 months. Of 52 patients, 17 (33%) were not enrolled on a Phase I trial due to decline in PS (n=13) or decision to pursue other treatments (n=4). Of 35 patients evaluable for response, 2 (6%) had a partial response (PR), and 3 (9%) had stable disease > 4 months. Prognostic factors analyzed include Hg < 10.5 g/dL, elevated CA 19-9 (>47 ng/mL), ECOG PS > 3, LDH > 618 IU/L, albumin < 3.5 g/dL, platelets < 150 K/UL, and number of metastatic sites. Full analysis including the mutational analysis for PIK3CA, KRAS, BRAF, TP53 is in progress. Median survival since presentation to the Phase I clinic was 4.1 months (range 2.3 - 30.8 months). Median overall survival from diagnosis was 23.9 months. The median survival since enrollment in a Phase I trial was 4.6 months w the median time to disease progression on Phase I treatment was 2.2 months (range 0.6 - 25.6 months). Conclusions: Prognosis of pts with CC and GC referred for phase I studies remains poor. Further analysis including complete mutational profiles of CC and GC patients will be reported.

Sign in / Sign up

Export Citation Format

Share Document